Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. lowered its holdings in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 8.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,612,964 shares of the company's stock after selling 247,883 shares during the period. Twist Bioscience accounts for 1.3% of Nikko Asset Management Americas Inc.'s investment portfolio, making the stock its 20th biggest position. Nikko Asset Management Americas Inc. owned about 4.38% of Twist Bioscience worth $121,372,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in TWST. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock worth $260,040,000 after buying an additional 237,772 shares during the last quarter. State Street Corp grew its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after acquiring an additional 526,028 shares during the period. Geode Capital Management LLC increased its stake in Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after acquiring an additional 26,145 shares during the last quarter. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the 3rd quarter worth about $43,992,000. Finally, Wellington Management Group LLP increased its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Robert W. Baird lifted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. TD Cowen reaffirmed a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 target price on the stock. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Finally, Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.40.

Twist Bioscience Stock Performance

TWST stock traded up $0.84 during trading on Friday, hitting $42.89. 1,319,967 shares of the company's stock traded hands, compared to its average volume of 923,444. The stock has a fifty day moving average price of $45.41 and a two-hundred day moving average price of $45.21. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The stock has a market capitalization of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The company's revenue for the quarter was up 24.1% compared to the same quarter last year. As a group, equities analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, CFO Adam Laponis sold 5,886 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company's stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dennis Cho sold 806 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares of the company's stock, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,552 shares of company stock valued at $1,500,289. Insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.